A Phase 1/2 Study of Donafenib in Combination With KN046 in Advanced Gastrointestinal Tumors

Suzhou Zelgen Biopharmaceuticals Co.,Ltd42 enrolled

Overview

This study is an open, multi-center clinical trial, the purpose is to study the safety and preliminary efficacy of Donafenib combined with KN046 in subjects with Advanced Gastrointestinal Tumors.

The study consists of dose escalation and dose expansion. The preset dose of Donafenib is 50 mg BID, 100 mg BID and 200 mg BID, and the preset dose of KN046 is 5 mg/kg Q3W. Dose expansion will enroll subjects who with advanced hepatocellular carcinoma.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Advanced Gastrointestinal Tumors

Interventions

Donafenib Tosilate TabletsDRUG

In the dose exploration phase (phase I) : three doses of Donafenib tosylate tablets \[50 mg twice a day; 100 mg twice a day; 200 mg twice a day \] will be explored. In the dose expansion phase (phase II), patients with advanced hepatocellular carcinoma will be treated at the recommended dose for phase 2(RP2D).The RP2D will be determined by the dose escalation study.

KN046 InjectionBIOLOGICAL

5mg/kg Q3W

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Male or female aged 18-70 years; * Phase I dose escalation: Advanced gastric cancer, esophageal cancer, colorectal cancer, hepatocellular carcinoma, pancreatic cancer (other than pancreatic neuroendocrine tumors) and intrahepatic cholangiocarcinoma that failed standard treatments confirmed by histopathology and/or cytology; Among them, the Child-Pugh score of liver function in patients with hepatocellular carcinoma is less than 5, * Phase II advanced hepatocellular carcinoma Dose expansion: Patients with advanced hepatocellular carcinoma who are clinically diagnosed or confirmed by histopathology and/or cytology and are not suitable for surgical resection; The patient has not undergone first-line systemic treatment \[small molecule targeted drugs (such as sorafenib, lenvatinib, etc.), systemic chemotherapy\] and tumor immunotherapy (anti-PD-1/L1, CTLA-4, etc.); Child-Pugh score of liver function ≤ 6; * Has at least one measurable lesion based on RECIST 1.1; * Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1; * Life expectancy ≥12 weeks; * Patients must be able to understand and willing to sign a written informed consent document. Exclusion Criteria: * Subjects who have previously received immune checkpoint inhibitors (such as anti-PD-1/L1, CTLA-4, etc.); * History of interstitial lung disease or non-infectious pneumonia; * Clinically obvious gastrointestinal abnormalities, which may affect the intake, transport or absorption of drugs (such as inability to swallow, chronic diarrhea, intestinal obstruction, etc.), or patients undergoing total gastrectomy; * Has received vaccination within 4 weeks prior to the first dose. * Has participated in other anticancer drug clinical trials within 4 weeks. * According to the judgement of the investigators, there are other factors that subjects are not suitable for the study.

Locations (1)

Zhongshan Hospital Affiliated to Fudan University

Shanghai, China

RECRUITING

Outcomes

Primary Outcomes

Phase I part - Tolerability of Donafenib in Combination With KN046

Evaluated by severity of drug-related adverse events (AEs), serious adverse events (SAEs).

Time frame: 21 days after the first dose of Donafenib and KN046

Phase II part - Objective response rate(ORR)

Objective response rate based on the RECIST 1.1 by investigator. Percentage of subjects achieving complete response (CR) and partial response (PR).

Time frame: From the time of initial administration until intolerant toxicity, disease progression, withdrawal of ICF, loss of follow-up, death or early study termination occurs (whichever occurs first),assessed up to 36 months]

Secondary Outcomes

Duration of Response (DOR)

It is defined as time between the date of first radiographic documented objective response and the date of the radiographic documented disease progression.

Time frame: Through study completion, an expected average of 3 year

Progression-Free Survival (PFS)

PFS is defined as the time from date of enrollment to the date of the first objectively documented tumor progression or death due to any cause.

Time frame: Through study completion, an expected average of 3 year

Central Contacts

Tianshu Liu, PhD

CONTACT

021-64041990 Liu.tianshu@zs-hospital.sh.cn

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.